INmune Bio Inc. (NASDAQ: INMB) Presents Cancer Treatment Immunotherapy at Congress of International Drug Discovery Science & Technology

August 2, 2019 10:15:45
  • INmune Bio attended the 17th Annual Congress of International Drug Discovery Science & Technology in Japan
  • Co-founder and CEO R.J. Tesi and Director of Neuroscience C.J. Barnum both participated in talks about the role of immunotherapy in the treatment of specific medical conditions
  • The congress was a paramount event in the field of immunotherapy, allowing researchers to network, exchange ideas and discuss recent developments

INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness patients’ innate immune systems to fight disease, presented its innovative cancer immunotherapy, as well as its Alzheimer’s disease drug candidate, during a major immunotherapy industry congress.

The 17th Annual Congress of International Drug Discovery Science & Technology, held on July 26 in Japan, brought together several immunotherapy industry leaders and provided excellent networking opportunities while facilitating the exchange of ideas and recent developments in the industry, as the company noted in a press release (

At the congress, INmune Bio co-founder and CEO R.J. Tesi, M.D, gave a talk titled ‘Combination Immunotherapy to Overcome Resistance to Cancer Treatments’, which highlighted monotherapy with checkpoint inhibitors (CPI) as an effective treatment option. The combination of CPI and other therapies may improve outcomes in patients who are unresponsive to monotherapy, Tesi explained.

INmune Bio Director of Neuroscience C.J. Barnum also delivered a presentation on immunological disease and neurodegenerative disease, titled ‘Neurodegenerative Disease as an Immunological Disease: Role of Biomarkers’. The presentation focused on the link between neuroinflammation and Alzheimer’s disease, as well as the INmune phase I trial evaluating the treatment of patients with dementia through a precision medicine approach.

The company’s innovative drug candidate, XPro1595, targets neuroinflammation. It works by affecting microglial immune cells in the brain. Research suggests that these cells get activated in many patients with Alzheimer’s disease, contributing to neuroinflammation and promoting synaptic dysfunction.

A phase I clinical trial of XPro1595 involves 18 patients and is expected to continue throughout the summer of 2019. INmune Bio aims to measure both traditional and novel biomarkers in the patients to assess inflammation in those who have mild to moderate Alzheimer’s disease. The Alzheimer’s Association is providing financial support for the clinical trial in the form of a $1 million grant.

As the prominence of Alzheimer’s disease increases, seeking an adequate treatment option is becoming a more important task than ever before. Studies show that the prevalence of Alzheimer’s disease doubles every five years, and it already affects 40 percent of the population in the 90-94 age group ( The prevalence of Alzheimer’s disease is also anticipated to grow in the 65+ age group. In 2000, 6.8 percent of people in that age group were affected, but the figure will reach 16.2 percent by 2050.

INmune Bio is a publicly traded clinical-stage biotechnology company focusing on the development of therapies that target the immune system to fight or control disease. Currently, the company is working on three product platforms – two products that modify patients’ innate immune responses to cancer and one product, XPro1595, that targets neuroinflammation linked to Alzheimer’s disease. All of the INmune Bio product platforms utilize a precision medicine approach for the treatment of a variety of hematologic malignancies, solid tumors and chronic inflammation.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office